BioSpace News Archive

Drug Development

Amgen Presents New Phase 2 Data That Show Olpasiran Delivers Significant Reduction in Lipoprotein(a) Levels

Amgen presented end-of-treatment data from its Phase 2 OCEAN-DOSE study of investigational olpasiran in adults with elevated lipoprotein [Lp] levels and a history of atherosclerotic cardiovascular disease.

November 6, 2022
·
12 min read
BioMidwest

New Data Show Onduo by Verily Significantly Improves Glycemic Levels Among Employees Living with Type 2 Diabetes at American Heart Association’s Scientific Sessions 2022

New, independently evaluated data presented at the American Heart Association’s Scientific Sessions show that use of the chronic care digital platform, Onduo by Verily, led to clinically significant improvements in blood glucose and cholesterol levels among participants of an employer-sponsored type 2 diabetes management program within the first year of participation.

November 6, 2022
·
4 min read
Drug Development

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Biologics, Inc. announces that the results of a phase 3 clinical study of tafolecimab, a recombinant fully human anti-PCSK-9 monoclonal antibody, in Chinese patients with non-familial hypercholesterolemia were presented at the American Heart Association Scientific Sessions 2022 as an e-poster.

November 6, 2022
·
10 min read